VRX : Analysis & Opinions

  1. Emergent BioSolutions Buys EV-035 Series from Evolva - Analyst ...

    December 18, 2014
    Emergent BioSolutions Inc. announced that it has entered into an agreement with Evolva Holding for acquiring the latter's ...
  2. UCB's Kremers Urban Sale Deal Lapses, Divestiture Plan On - Analyst ...

    December 18, 2014
    UCB (UCBJF), Advent International and Avista Capital Partners announced their decision to mutually terminate their deal for ...
  3. Cyclacel Falls on Poor Acute Myeloid Leukemia Drug Data - Analyst ...

    December 17, 2014
    In the SEAMLESS study on sapacitabine, the DSMB found that the planned futility boundary has been crossed.
  4. Alexion Announces New Share Repurchase Program of $500M - Analyst ...

    December 16, 2014
    Alexion Pharmaceuticals, Inc. (ALXN) announced that a new share repurchase program of up to $500 million have been authorized ...
  5. ChemoCentryx Up on Positive Diabetic Nephropathy Data - Analyst ...

    December 15, 2014
    ChemoCentryx, Inc., announced positive top-line 52-week data from its phase II study on its candidate CCX140 for diabetic ...
  6. Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook

    November 18, 2014
    Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
  7. Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry ...

    July 24, 2014
    Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
  8. Four Breakout Stocks To Watch

    February 19, 2014
    These biotechnology and pharmaceutical stocks continue to put in new highs, but indicators are diverging.
  9. Bull of the Day: Valeant Pharma (VRX) - Bull of the Day

    October 13, 2013
    Bull of the Day: Valeant Pharma (VRX) - Bull of the Day
  10. After A Sharp Pullback, Is Allergan Pretty Enough?

    July 31, 2013
    Down on fears about generics and the pipeline, the Street may be underestimating Allergan
  11. Abbott Adds Two Promising Products

    July 15, 2013
    Abbott makes two solid growth acquisitions that should address large markets.
  12. Santarus Achieves New 52-Week High - Analyst Blog

    July 9, 2013
    Share price of Santarus reached a new 52-week high on Jul 8, 2013.
  13. Valeant Eyes Bausch & Lomb

    May 28, 2013
    Canadian pharmaceutical company Valeant has made a name for itself through acquisitions. On May 27 it announced that it was ...
  14. A Good Deal For Actavis, But Warner Chilcott Goes A Little Cheap

    May 21, 2013
    Actavis gets a very useful asset, while Warner Chilcott shareholders get a decent exit.
  15. Adasuve Deal Is Very Good For Alexza, But What About Teva?

    May 9, 2013
    Teva's partnership with Alexza looks like an expensive gamble.
  16. ARIAD Closes Offering of Shares - Analyst Blog

    January 30, 2013
    ARIAD Pharmaceuticals, Inc. (ARIA) recently announced the closure of its previously announced public offering. ARIAD Pharma ...
  17. Pipeline Advances at Exelixis - Analyst Blog

    January 18, 2013
    Exelixis, Inc. (EXEL) recently announced that it has received a notice from its partner, Roche Holding (RHHBY), regarding ...
  18. Isis Pharma Updates on its Pipeline - Analyst Blog

    January 11, 2013
    Isis Pharmaceuticals, Inc. (ISIS) recently provided an update on its pipeline. Isis Pharma boasts of a robust pipeline. The ...
  19. Impax Launches Opana ER Generic - Analyst Blog

    January 7, 2013
    Global Pharmaceuticals, the generic division of Impax Laboratories, Inc. (IPXL), a specialty pharmaceutical company, recently ...
  20. Elan Hives Off Prothena - Analyst Blog

    December 27, 2012
    Elan Corporation, plc (ELN), a neuroscience-based biotechnology company, recently completed the separation of a significant ...
  21. Your Stock's Earnings Yield - Screen of the Week

    December 11, 2012
    A stock's Earnings Yield measures just that, the anticipated yield (or return) an investment in a stock could give you based ...
  22. Medicis, Revance Settle Litigation - Analyst Blog

    October 15, 2012
    Privately owned specialty biopharmaceutical company, Revance Therapeutics, Inc. recently announced the termination of its ...
  23. Valeant Works Its Mojo With Medicis

    September 7, 2012
    Valeant makes a bold but logical bid for Medicis.
  24. Valeant Pharmaceuticals Int (USA) and Other Healthcare Stocks ...

    August 15, 2012
    The Nasdaq is trading up 0.2%, the S&P 500 has remained steady and the Dow remains relatively unchanged so far today. ...
  25. Novo Nordisk A/S (ADR) and Other Big Movers In Healthcare

    August 14, 2012
    The Nasdaq has climbed 0.6%, the S&P 500 is up 0.3% and the Dow has risen 0.3%, marking a bad morning for the market. ...
  26. Biggest Healthcare Sector Movers for July 3, 2012

    July 3, 2012
    The market is doing well so far today. The Nasdaq has moved up 0.7%; the S&P 500 is up 0.7%; and the Dow has risen 0.6%. ...
  27. Obagi Puts Its Problems Behind It

    May 25, 2012
    A year ago, Obagi Medical Products faced some problems in Texas that presented an investment opportunity. One year later ...
  28. Stocks To Buy On A Market Sell-Off

    March 8, 2012
    A market pullback will create a buying opportuntiy for some of the top performing stocks.
  29. The Salix Story Keeps Improving

    January 18, 2012
    Salix is a great candidate for growth investors.
  30. Can The Big Gains Continue Into 2012?

    January 3, 2012
    Learn the opportunities and risks that await some top performers in 2012.
  31. 2011 In Review - Pharmaceuticals

    December 29, 2011
    2011 was a surprisingly healthy year for drug stocks.
  32. Canada Is Key For A Strong Portfolio

    November 10, 2011
    With the majority of the developed world still facing problems, Canada is beacon of growth.
  33. Covidien's Image Starting To Change

    August 3, 2011
    Find out why Covidien is much better than many investors assume.
Trading Center